

Polygenic Associations and Causal Inferences between Serum Immunoglobulins and Amyotrophic Lateral Sclerosis

Xu Chen, PhD^{1,2}; Xiaojun Shen, BSc²; Yiqiang Zhan, PhD^{3,4}; Fang Fang, MD, PhD³

From the ¹Department of Central Laboratory and ²Institute for Maternal-Fetal Medicine, Baoan Women's and Children's Hospital, Jinan University, Shenzhen, China; ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ⁴German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

Corresponding author: Dr. Xu Chen. Department of Central Laboratory, Baoan Women's and Children's Hospital, No.56 YuLv Road, 518100 Shenzhen, China. Phone: +86-15989385199. Email: dr.xuchen@outlook.com.

Running head: Immunoglobulins and ALS

Number of words in the abstract: 212

Number of words in the main text: 1505

Number of figures: 0

Number of tables: 2

19 **Abstract**

20 Chronic inflammation might contribute to the development of amyotrophic lateral sclerosis (ALS).
21 The relationship between serum immunoglobulins and risk of ALS remains however greatly
22 unknown. In order to overcome limitations like reverse causation and residual confounding
23 commonly seen in observational studies, we applied polygenic risk score (PRS) and Mendelian
24 randomization (MR) analyses on summary statistics from the large-scale genome-wide association
25 studies (GWAS), to examine the polygenic and causal associations between three serum
26 immunoglobulins (IgA, IgM, and IgG) and risk of ALS (first in a discovery phase and then in a
27 replication phase). An inverse polygenic association was discovered between IgA and ALS as well
28 as between IgM and ALS. Such associations were however not replicated using a larger ALS GWAS
29 and no causal association was observed for either IgA-ALS or IgM-ALS. A positive polygenic
30 association was both discovered [odds ratio (OR) = 1.18; 95% confidence interval (CI): 1.12-1.25,
31 $P=5.9 \times 10^{-7}$] and replicated (OR=1.13, 95% CI: 1.06-1.20, $P=0.001$) between IgG and ALS. A causal
32 association between IgG and ALS was also suggested in both the discovery (OR=1.06, 95%CI: 1.02-
33 1.10, $P=0.009$) and replication (OR=1.07, 95%CI: 0.90-1.24, $P=0.420$) analyses, although the latter
34 was not statistically significant. This study suggests a shared polygenic risk between serum IgG (as a
35 biomarker for chronic inflammation) and ALS.

36 **Introduction**

37 Amyotrophic lateral sclerosis (ALS) is a relatively rare but fatal neurodegenerative disease. Chronic
38 inflammation and altered immune responses have been suggested to contribute to the pathogenesis
39 of ALS.^{1, 2} The relationship between serum immunoglobulins, as known biomarkers for
40 inflammation and immune responses, and risk of ALS remains however greatly unknown. In a
41 previous study, we did not find a statistically significant positive association between
42 immunoglobulin G (IgG) and risk of ALS [hazard ratio=1.04; 95% confidence interval (CI): 0.89-
43 1.22; per 2.99 g/L increase of IgG].³ In the same study, we found also that during the 20 years before
44 diagnosis, patients with ALS had more rapidly declining levels of IgG compared to others.³ We
45 speculate that the noted lack of association between IgG and ALS might be attributable to both a real
46 positive association between IgG and ALS (i.e., higher levels of IgG lead to higher risk of ALS) and
47 reverse causation (i.e., ALS results in declined levels of IgG). In addition to reverse causation,
48 observational studies are also prone to other systemic errors, which collectively make it often
49 difficult to infer causality for associations noted in observational studies.⁴

50 By using the summary statistics from large-scale genome-wide association studies (GWAS),
51 polygenic risk score (PRS) and Mendelian randomization (MR) analyses have added novel evidence
52 to support polygenic and causal relationships between several traits and ALS, corroborating
53 importantly findings from previous observational studies.⁵⁻⁷ In this study, we aimed to examine the
54 polygenic association and infer the causality between IgG and risk of ALS, using summary statistics
55 from GWAS of serum immunoglobulins and ALS. Because IgG is a biomarker for chronic
56 inflammation, we hypothesized that there is a positive and causal relationship between IgG and ALS.
57 We additionally studied another two serum immunoglobulins (IgA and IgM) to assess the specificity
58 of the IgG result. The roles of these two biomarkers have rarely been studied in ALS.

59 **Materials and Methods**

60 *Summary statistics*

61 We used publicly available summary statistics of several GWAS within the European ancestry
62 population in this study. GWAS of serum immunoglobulins (IgA, IgM, and IgG) were conducted
63 among ~15000 individuals, from which single nucleotide polymorphisms (SNPs) with the
64 association P-values $<1.0 \times 10^{-6}$ were available.⁸ GWAS summary statistics of ALS were obtained
65 from two studies (available in the IEU GWAS database; <https://gwas.mrcieu.ac.uk>, ID for
66 ALS_2016: ieu-a-1085; ID for ALS_2018: ebi-a-GCST005647). In the discovery analysis, summary
67 statistics of ALS (ALS_2016) were obtained from a GWAS performed among 36052 individuals
68 (including 12577 patients with ALS and 23475 controls) by the Project MinE group.⁹ In the
69 replication analysis, summary statistics of ALS (ALS_2018) were obtained from a meta-analysis
70 incorporating the results from ALS_2016 and another GWAS including 44558 individuals (8229
71 patients with ALS and 32369 controls).¹⁰

72 Using IgA, IgM, and IgG as the exposures (base traits) and ALS as the outcome (target trait),
73 the polygenic and causal associations of six exposure-outcome pairs (three in the discovery analysis
74 and three in the replication analysis) were investigated by PRS and MR analyses, respectively.
75 Because the values of immunoglobulins were standardized in the GWAS, we estimated accordingly
76 odds ratio (OR) per standard deviation of genetically determined level for each type of
77 immunoglobulin in the present study.

78

79 *PRS analyses*

80 Polygenic associations were investigated by PRS analyses in Linux with PRSice package (version
81 1.25).¹¹ For the summary statistics of each exposure, correlated SNPs were pruned by linkage

82 disequilibrium (LD) clumping with default parameter settings. Genotypes of the HapMap_ceu_all
83 (release 22, 60 individuals, 3.96 million SNPs) were used as the reference panel, clumping threshold
84 $p_1=p_2=0.5$, LD threshold $r^2=0.05$, and the distance threshold of 300Kb. Independent SNPs were then
85 extracted and included in 100000 quantiles with gradually increasing P-value thresholds (P_T , ranging
86 from 0 to 1.0×10^{-6} , in steps of 1.0×10^{-11} per quantile). The P_T of the quantile that explained the
87 largest variance of the target was defined as the best-fitted P_T .

88

89 *MR analyses*

90 Causal inferences were performed by MR analyses in R (version 3.6.1) with TwoSampleMR
91 package (version 0.5.2).¹² Lead SNPs from the genetic loci reported to be associated with each
92 exposure were extracted from the GWAS of immunoglobulins.⁸ The associations of the SNPs with
93 other traits (associations with a P-value $<5 \times 10^{-8}$) were checked in GWAS Catalog
94 (<https://www.ebi.ac.uk/gwas>) and excluded, leaving independent lead SNPs after LD clumping as
95 the instrumental variables (IVs, Supplementary Table 1). The causal relationship of each exposure-
96 outcome pair was primarily examined by the inverse variance weighted (IVW) method and
97 complemented with another four methods (MR Egger regression, weighted median, simple and
98 weighted mode) as sensitivity analyses.

99

100

101 **Results**

102 Inverse polygenic associations were discovered for IgA-ALS and IgM-ALS (Table 1). Neither of the
103 associations was however replicated (Supplementary Figures 1-2). A positive polygenic association
104 between IgG and ALS was found both in the discovery and replication analyses (Supplementary

105 Figure 3). The OR was 1.18 (95% CI: 1.12-1.25, $P=5.9\times 10^{-7}$) in the discovery analysis and 1.13
106 (95%CI: 1.06-1.20, $P=0.001$) in the replication analysis.

107 In the MR analyses, causal association was not found for either IgA-ALS or IgM-ALS (Table
108 2), regardless of the use of MR methods (Supplementary Table 2 and Supplementary Figures 4-5).
109 For IgG-ALS, a statistically significant causal association was found in the discovery analysis
110 (OR=1.06, 95% CI: 1.02-1.10, $P=0.009$). A causal positive association was also suggested in the
111 replication analysis, although not statistically significant (OR=1.07, 95%CI: 0.90-1.24, $P=0.420$).

112

113

114 **Discussion**

115 Utilizing PRS and MR analyses of large-scale GWAS of immunoglobulins and ALS, we provided
116 new evidence supporting a potentially causal positive association between IgG, but not IgA or IgM,
117 and risk of ALS.

118 Accumulating evidence supports that inflammation and altered immune responses are
119 involved in the different phases of ALS.¹³ Physiological barriers (e.g., blood-brain barrier) and
120 innate immunity cells (e.g., macrophages) are fundamental in the maintenance and modulation of the
121 central nervous system, whereas chronic inflammation might lead to dysfunction of the neurons.¹⁴ B
122 cells play important roles in adaptive immunity, through producing immunoglobulins and presenting
123 antigens to T cells.¹⁵ IgA constitutes 10-20% of serum immunoglobulins and is mainly involved in
124 the mucosal immune response. IgM constitutes 5-10% of serum immunoglobulins and is the earliest
125 released antibody during adaptive immune response. IgG constitutes ~75% of serum
126 immunoglobulins and can be transmitted through placental and blood-brain barriers.¹⁶ Few studies
127 have however examined the roles of these immunoglobulins in ALS to our knowledge. In our

128 previous cohort study including more than half a million participants with >20 years of follow-up,
129 we found that per 2.99 g/L increase of IgG levels in blood, there was a 4% increased risk of ALS,
130 although the association was not statistically significant.³ The lack of statistical significance might
131 be multifactorial, including first a potentially real positive association between IgG and ALS risk, a
132 lack of statistical power due to the relatively small number of ALS cases identified (N=152), and
133 also reverse causation (i.e., patients with ALS had more rapidly declining IgG levels, compared to
134 individuals not developing ALS, during the 20 years before ALS diagnosis).³

135 By using summary statistics from several large-scale GWAS, in the present study, we
136 identified a statistically significant positive polygenic association between IgG and ALS in both the
137 discovery and replication analyses. The association is further suggested to be causal in the MR
138 analysis. Although statistically significant result was only obtained in the discovery analysis, similar
139 point estimate was noted in the replication analysis. The differences between the discovery
140 (ALS_2016) and replication (ALS_2018) samples might have contributed to the lack of statistical
141 significance in the replication analysis. For instance, in the discovery GWAS (ALS_2016), patients
142 with ALS and controls were matched for age, sex, and geographic regions, whereas in the replication
143 GWAS (ALS_2018) >50% of participants were only matched for race/ethnicity. In contrast to IgG,
144 no clear polygenic association nor causal relationship was noted for IgA-ALS and IgM-ALS. This
145 different result pattern might be partly explained by the fact that IgG is a biomarker for chronic
146 inflammation and bypasses the blood-brain-barrier, which might be more relevant for
147 neurodegenerative diseases including ALS, compared to the other immunoglobulins.¹⁷

148 Causal inference by MR analysis requires three basic assumptions: 1) relevance, i.e., IVs
149 have causal effects on the exposure such as IgG; 2) exclusion restriction, i.e., IVs affect the outcome,
150 such as ALS, only through the exposure; and 3) exchangeability or independence, i.e., no common

151 causes between IVs and the outcome.¹⁸ Even though we used the latest and largest GWAS of
152 immunoglobulins, only two independent SNPs could be selected as IVs for IgG. As a result, we
153 could only use IVW methods in the MR analysis. According to the current GWAS Catalog, no
154 genome-wide significant association was identified between the two IVs of IgG and other non-ALS
155 traits. Interestingly, the two genes near these two IVs (*FCGR2B* near rs7554873 and *HLA-DQB1*
156 near rs2133037) are both biologically related to immune responses, neuroinflammation, and
157 neurodegeneration.^{19, 20}

158 In conclusion, our study suggests a shared polygenic risk between serum IgG and ALS. The
159 causality between IgG and ALS needs to be further validated when more instrumental variables are
160 available and when different methods of causal inference are possible to use.

161

162

163 **Acknowledgment**

164 The authors would like to thank the Project MinE group and the ALS Variant Server for sharing the
165 summary statistics of GWAS on ALS. This project is partly supported by the Swedish Research
166 Council (Grant No.: 2019-01088) and Karolinska Institutet (Senior Researcher Award and Strategic
167 Research Area in Epidemiology).

168

169 **Author Contributions**

170 X.C. and F.F. contributed to the conception and design of the study; X.C., X.S., and Y.Z. contributed
171 to acquisition and analyses of data; X.C., X.S., Y.Z., and F.F. contributed to drafting and revising the
172 manuscript.

173

174 **Potential Conflicts of Interest**

175 Noting to report.

176

177 **References**

- 178 1. Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms
179 and emerging therapies. *Lancet Neurol*. 2019 Feb;18(2):211-20.
- 180 2. Hammond TR, Marsh SE, Stevens B. Immune Signaling in Neurodegeneration. *Immunity*.
181 2019 Apr 16;50(4):955-74.
- 182 3. Yazdani S, Mariosa D, Hammar N, et al. Peripheral immune biomarkers and
183 neurodegenerative diseases: A prospective cohort study with 20 years of follow-up. *Ann Neurol*.
184 2019 Dec;86(6):913-26.
- 185 4. Vandembroucke JP, Broadbent A, Pearce N. Causality and causal inference in epidemiology:
186 the need for a pluralistic approach. *Int J Epidemiol*. 2016 Dec 1;45(6):1776-86.
- 187 5. Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and
188 amyotrophic lateral sclerosis. *Neurobiol Aging*. 2018 Jul;67:202 e1- e6.
- 189 6. Bandres-Ciga S, Noyce AJ, Hemani G, et al. Shared polygenic risk and causal inferences in
190 amyotrophic lateral sclerosis. *Ann Neurol*. 2019 Apr;85(4):470-81.
- 191 7. Zhan Y, Fang F. Smoking and amyotrophic lateral sclerosis: A mendelian randomization
192 study. *Ann Neurol*. 2019 Apr;85(4):482-4.
- 193 8. Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, et al. Identification of sequence
194 variants influencing immunoglobulin levels. *Nat Genet*. 2017 Aug;49(8):1182-91.
- 195 9. van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify
196 new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet*. 2016
197 Sep;48(9):1043-8.
- 198 10. Nicolas A, Kenna KP, Renton AE, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS
199 Gene. *Neuron*. 2018 Mar 21;97(6):1268-83 e6.
- 200 11. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. *Bioinformatics*.
201 2015 May 1;31(9):1466-8.
- 202 12. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal
203 inference across the human phenome. *Elife*. 2018 May 30;7.

- 204 13. Molteni M, Rossetti C. Neurodegenerative diseases: The immunological perspective. *J*
205 *Neuroimmunol.* 2017 Dec 15;313:109-15.
- 206 14. Novellino F, Sacca V, Donato A, et al. Innate Immunity: A Common Denominator between
207 Neurodegenerative and Neuropsychiatric Diseases. *Int J Mol Sci.* 2020 Feb 7;21(3).
- 208 15. Sabatino JJ, Jr., Probstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative
209 central nervous system diseases. *Nat Rev Neurosci.* 2019 Dec;20(12):728-45.
- 210 16. Chen K, Magri G, Grasset EK, Cerutti A. Rethinking mucosal antibody responses: IgM, IgG
211 and IgD join IgA. *Nat Rev Immunol.* 2020 Feb 3.
- 212 17. Watson N, Ding B, Zhu X, Frisina RD. Chronic inflammation - inflammaging - in the ageing
213 cochlea: A novel target for future presbycusis therapy. *Ageing Res Rev.* 2017 Nov;40:142-8.
- 214 18. Armon C. Smoking is a cause of amyotrophic lateral sclerosis. High low-density lipoprotein
215 cholesterol levels? Unsure. *Ann Neurol.* 2019 Apr;85(4):465-9.
- 216 19. Choi YR, Kang SJ, Kim JM, et al. FcγRIIB mediates the inhibitory effect of aggregated
217 alpha-synuclein on microglial phagocytosis. *Neurobiol Dis.* 2015 Nov;83:90-9.
- 218 20. Hallberg P, Smedje H, Eriksson N, et al. Pandemrix-induced narcolepsy is associated with
219 genes related to immunity and neuronal survival. *EBioMedicine.* 2019 Feb;40:595-604.
- 220

221 TABLES

222 **TABLE 1. Polygenic Associations between Serum Immunoglobulins and ALS in PRS Analyses**

Base	Target	Best-fitted P_T	n_{SNP}	OR	SE	r^2 (%)	P-value
IgA	ALS_2016	8.6000×10^{-10}	54	0.861	0.032	0.059	4.2×10^{-6}
	ALS_2018	7.0001×10^{-7}	43	0.948	0.031	0.004	0.085
IgM	ALS_2016	4.8000×10^{-10}	47	0.905	0.032	0.028	0.002
	ALS_2018	3.5010×10^{-8}	42	1.051	0.028	0.004	0.074
IgG	ALS_2016	5.1001×10^{-7}	49	1.181	0.033	0.069	5.9×10^{-7}
	ALS_2018	5.7001×10^{-7}	22	1.130	0.036	0.014	0.001

223 PRS=polygenic risk score; ALS=amyotrophic lateral sclerosis; Best-fitted P_T =association P-value
224 threshold of the quantile that explained the largest variance of the target; n_{SNP} =numbers of
225 independent single nucleotide polymorphisms (SNPs) included in the best-fitted quantile; OR: odds
226 ratio per standard deviation of genetically determined level for each type of immunoglobulin;
227 SE=standard error; r^2 = the proportion of the target variation explained by SNPs in the best-fitted
228 quantile.

229

230

231 **TABLE 2. Causal Inferences between Serum Immunoglobulins and ALS in the MR Analyses**

Base	Target	n _{SNP}	OR _{IVW}	SE _{IVW}	P _{IVW}	Het_P _{IVW}
IgA	ALS_2016	6	0.968	0.022	0.148	0.206
	ALS_2018	6	0.880	0.100	0.201	0.125
IgM	ALS_2016	5	0.996	0.015	0.787	0.574
	ALS_2018	5	1.021	0.054	0.706	0.874
IgG	ALS_2016	2	1.056	0.021	0.009	0.617
	ALS_2018	2	1.073	0.087	0.420	0.407

232 MR=mendelian randomization; ALS=amyotrophic lateral sclerosis; n_{SNP}= numbers of independent
233 single nucleotide polymorphisms (SNPs) uses as instrumental variables; OR: odds ratio per standard
234 deviation of genetically determined level for each type of immunoglobulin; SE=standard error;
235 IVW= inverse variance weighted method; Het_P=P-value of heterogeneity.